Trinity Biotech plc Upgraded by Zacks to “Outperform” (TRIB)
Trinity Biotech plc (NASDAQ:TRIB) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research report issued on Tuesday, ARN reports. The firm currently has a $23.10 price target on the stock. Zacks‘ target price suggests a potential upside of 6.16% from the company’s current price.
Shares of Trinity Biotech plc (NASDAQ:TRIB) traded up 2.48% during mid-day trading on Tuesday, hitting $22.30. 87,246 shares of the company’s stock traded hands. Trinity Biotech plc has a 52-week low of $13.51 and a 52-week high of $22.00. The stock has a 50-day moving average of $20.08 and a 200-day moving average of $17.96. The company has a market cap of $483.1 million and a price-to-earnings ratio of 29.25.
Trinity Biotech plc (NASDAQ:TRIB) last released its earnings data on Tuesday, July 30th. The company reported $0.21 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.20 by $0.01. The company had revenue of $21.30 million for the quarter, compared to the consensus estimate of $22.03 million. On average, analysts predict that Trinity Biotech plc will post $0.80 earnings per share for the current fiscal year.
Trinity Biotech plc (NASDAQ:TRIB) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.